167 related articles for article (PubMed ID: 38138894)
1. Survival Outcomes and Health-Related Quality of Life in Older Adults Diagnosed with Acute Myeloid Leukemia Receiving Frontline Therapy in Daily Practice.
Ramos F; Hermosín ML; Fuertes-Núñez M; Martínez P; Rodriguez-Medina C; Barrios M; Ibáñez F; Bernal T; Olave MT; Álvarez MÁ; Vahí M; Caballero-Velázquez T; González B; Altés A; García L; Fernández P; Durán MA; López R; Rafel M; Serrano J
J Pers Med; 2023 Nov; 13(12):. PubMed ID: 38138894
[TBL] [Abstract][Full Text] [Related]
2. Characteristics and outcomes of older patients with secondary acute myeloid leukemia according to treatment approach.
Boddu PC; Kantarjian HM; Ravandi F; Garcia-Manero G; Verstovsek S; Jabbour EJ; Takahashi K; Bhalla K; Konopleva M; DiNardo CD; Ohanian M; Pemmaraju N; Jain N; Pierce S; Wierda WG; Cortes JE; Kadia TM
Cancer; 2017 Aug; 123(16):3050-3060. PubMed ID: 28387922
[TBL] [Abstract][Full Text] [Related]
3. Treatment outcomes for newly diagnosed, treatment-naïve TP53-mutated acute myeloid leukemia: a systematic review and meta-analysis.
Daver NG; Iqbal S; Renard C; Chan RJ; Hasegawa K; Hu H; Tse P; Yan J; Zoratti MJ; Xie F; Ramsingh G
J Hematol Oncol; 2023 Mar; 16(1):19. PubMed ID: 36879351
[TBL] [Abstract][Full Text] [Related]
4. Health-related quality of life in patients with microsatellite instability-high or mismatch repair deficient metastatic colorectal cancer treated with first-line pembrolizumab versus chemotherapy (KEYNOTE-177): an open-label, randomised, phase 3 trial.
Andre T; Amonkar M; Norquist JM; Shiu KK; Kim TW; Jensen BV; Jensen LH; Punt CJA; Smith D; Garcia-Carbonero R; Sevilla I; De La Fouchardiere C; Rivera F; Elez E; Diaz LA; Yoshino T; Van Cutsem E; Yang P; Farooqui M; Le DT
Lancet Oncol; 2021 May; 22(5):665-677. PubMed ID: 33812497
[TBL] [Abstract][Full Text] [Related]
5. Outcomes and health care utilization of older patients with acute myeloid leukemia.
Sharplin K; Wee LYA; Singhal D; Edwards S; Danner S; Lewis I; Thomas D; Wei A; Yong ASM; Hiwase DK
J Geriatr Oncol; 2021 Mar; 12(2):243-249. PubMed ID: 32713804
[TBL] [Abstract][Full Text] [Related]
6. Treatment regimens in patients over 64 years with acute myeloid leukaemia: a retrospective single-institution, multi-site analysis.
Sutter T; Schittenhelm M; Volken T; Lehmann T
Hematology; 2023 Dec; 28(1):2206694. PubMed ID: 38078486
[TBL] [Abstract][Full Text] [Related]
7. Hypomethylating agents combined with low-dose chemotherapy for elderly patients with acute myeloid leukaemia unfit for intensive chemotherapy: a real-world clinical experience.
Chen Y; Cao J; Ye Y; Luo L; Zheng X; Yang X; Zheng Z; Zheng J; Yang T; Hu J
J Chemother; 2023 Jul; 35(4):322-329. PubMed ID: 35881409
[TBL] [Abstract][Full Text] [Related]
8. Parameters detected by geriatric and quality of life assessment in 195 older patients with myelodysplastic syndromes and acute myeloid leukemia are highly predictive for outcome.
Deschler B; Ihorst G; Platzbecker U; Germing U; März E; de Figuerido M; Fritzsche K; Haas P; Salih HR; Giagounidis A; Selleslag D; Labar B; de Witte T; Wijermans P; Lübbert M
Haematologica; 2013 Feb; 98(2):208-16. PubMed ID: 22875615
[TBL] [Abstract][Full Text] [Related]
9. Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure.
Short NJ; Venugopal S; Qiao W; Kadia TM; Ravandi F; Macaron W; Dinardo CD; Daver N; Konopleva M; Borthakur G; Shpall EJ; Popat U; Champlin RE; Mehta R; Al-Atrash G; Oran B; Jabbour E; Garcia-Manero G; Issa GC; Montalban-Bravo G; Yilmaz M; Maiti A; Kantarjian H
J Hematol Oncol; 2022 Jan; 15(1):12. PubMed ID: 35093134
[TBL] [Abstract][Full Text] [Related]
10. Intensive chemotherapy vs. hypomethylating agents in older adults with newly diagnosed high-risk acute myeloid leukemia: A single center experience.
Vachhani P; Al Yacoub R; Miller A; Zhang F; Cronin TL; Ontiveros EP; Thompson JE; Griffiths EA; Wang ES
Leuk Res; 2018 Dec; 75():29-35. PubMed ID: 30445237
[TBL] [Abstract][Full Text] [Related]
11. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma - clinical application of health-related quality-of-life data.
Li L; Mo FK; Chan SL; Hui EP; Tang NS; Koh J; Leung LK; Poon AN; Hui J; Chu CM; Lee KF; Ma BB; Lai PB; Chan AT; Yu SC; Yeo W
BMC Cancer; 2017 Jan; 17(1):8. PubMed ID: 28052758
[TBL] [Abstract][Full Text] [Related]
12. Not type of induction therapy but consolidation with allogeneic hematopoietic cell transplantation determines outcome in older AML patients: A single center experience of 355 consecutive patients.
Hilberink J; Hazenberg C; van den Berg E; Mulder A; Schuringa JJ; van der Helm L; de Groot M; Choi G; de Bock GH; Vellenga E; Ammatuna E; Huls G
Leuk Res; 2019 May; 80():33-39. PubMed ID: 30954622
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic decision-making in elderly patients with acute myeloid leukemia: conventional intensive chemotherapy versus hypomethylating agent therapy.
Oh SB; Park SW; Chung JS; Lee WS; Lee HS; Cho SH; Choi YS; Lim SN; Shin HJ;
Ann Hematol; 2017 Nov; 96(11):1801-1809. PubMed ID: 28828639
[TBL] [Abstract][Full Text] [Related]
14. Therapies for acute myeloid leukemia in patients ineligible for standard induction chemotherapy: a systematic review.
Heuser M; Fernandez C; Hauch O; Klibanov OM; Chaudhary T; Rives V
Future Oncol; 2023 Apr; 19(11):789-810. PubMed ID: 37170899
[TBL] [Abstract][Full Text] [Related]
15. Clinical outcome of older adults with acute myeloid Leukemia: An analysis of a large tertiary referral Center over two decades.
Ihlow J; Gross S; Neuendorff NR; Busack L; Herneth A; Singh A; Schwarz M; Flörcken A; Anagnostopoulos I; Türkmen S; Burmeister T; Blau IW; Bullinger L; Westermann J
J Geriatr Oncol; 2021 May; 12(4):540-549. PubMed ID: 33223482
[TBL] [Abstract][Full Text] [Related]
16. Predictive factors for response and survival in elderly acute myeloid leukemia patients treated with hypomethylating agents: a real-life experience.
Pepe S; Scalzulli E; Colafigli G; Di Prima A; Diverio D; Mancini M; Latagliata R; Martelli M; Foà R; Breccia M
Ann Hematol; 2020 Oct; 99(10):2405-2416. PubMed ID: 32813071
[TBL] [Abstract][Full Text] [Related]
17. Geriatric assessment in hematology scale predicts treatment tolerability in older patients diagnosed with hematological malignancies: The RETROGAH study.
de la Rubia J; González B; Cruz-Jentoft AJ; Iglesias L; Jarque I; Persona EP; Lluch R; Marrero C; Zudaire M; Gironella M; Hernández-Rivas JÁ; Arnan M; Olivier C; Encinas C; Soler JA; Payer ÁR; Casado A; Fernández P; Vilanova D; Bonanad S
J Geriatr Oncol; 2023 Jan; 14(1):101401. PubMed ID: 36404260
[TBL] [Abstract][Full Text] [Related]
18. Impact of frontline treatment approach on outcomes of myeloid blast phase CML.
Saxena K; Jabbour E; Issa G; Sasaki K; Ravandi F; Maiti A; Daver N; Kadia T; DiNardo CD; Konopleva M; Cortes JE; Yilmaz M; Chien K; Pierce S; Kantarjian H; Short NJ
J Hematol Oncol; 2021 Jun; 14(1):94. PubMed ID: 34130720
[TBL] [Abstract][Full Text] [Related]
19. [Comparison of Therapeutic Efficacy between Hypomenthylating Agents Combined with Venetoclax and Half Dose Priming Regimen in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia].
Xu MZ; Qiao M; Sun AN; Wu DP; Xue SL; Zhou HX
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Dec; 30(6):1631-1636. PubMed ID: 36476881
[TBL] [Abstract][Full Text] [Related]
20. Assessing the validity of EQ-5D-5L in people with head & neck cancer: Does a generic quality of life measure perform as well as a disease-specific measure in a patient population?
Davies A; Waylen A; Leary S; Thomas S; Pring M; Janssen B; Beynon R; Lang S; Schimansky S; Hurley K; Ness A
Oral Oncol; 2020 Feb; 101():104504. PubMed ID: 31835074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]